NEWS
Paul Hastings Advised Blackstone Life Sciences in Series B Financing of AvenCell Therapeutics
October 23, 2024
Paul Hastings LLP advised Blackstone Life Sciences in connection with AvenCell Therapeutics’ $112 million Series B financing led by Novo Holdings. AvenCell Therapeutics is a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies. Blackstone Life Sciences is a founding investor of AvenCell Therapeutics.
Partner Samuel Waxman led the Paul Hastings team, which also included associates Adam Winer and Matthew Schob.
More details on the transaction can be found here.
About Paul Hastings
With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.
Practice Areas
Securities and Capital Markets
SIGN UP FOR NEWS INSIGHTS
MEDIA CONTACTS
M&A, Private Equity, Data Privacy and Cybersecurity, Investment Funds and Private Capital, Structured Credit, Life Sciences, Employment Law and Media and Entertainment
Natalie GewargisAntitrust and Competition, Global Finance, Litigation, Financial Restructuring, Intellectual Property, Fintech and Payments, Consumer Financial Services, International Arbitration, and Investigations and White Collar Defense
Becca Hatton